Bausch + Lomb (NYSE:BLCO) vs. Pulse Biosciences (NASDAQ:PLSE) Critical Contrast

Bausch + Lomb (NYSE:BLCO) and Pulse Biosciences (NASDAQ:PLSE) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.

Earnings & Valuation

This table compares Bausch + Lomb and Pulse Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10 billion	1.50	-$360.00 million	($0.31)	-68.87
Pulse Biosciences	$350,000.00	11,973.94	-$72.78 million	($1.21)	-47.09

Pulse Biosciences has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bausch + Lomb and Pulse Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-2.05%	5.01%	2.34%
Pulse Biosciences	-5,603.88%	-77.88%	-67.89%

Risk and Volatility

Bausch + Lomb has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

Institutional & Insider Ownership

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 1.4% of Bausch + Lomb shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Bausch + Lomb and Pulse Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1	8	4	2	2.47
Pulse Biosciences	1	0	5	1	2.86

Bausch + Lomb currently has a consensus price target of $20.83, indicating a potential downside of 2.42%. Pulse Biosciences has a consensus price target of $66.60, indicating a potential upside of 16.88%. Given Pulse Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Pulse Biosciences is more favorable than Bausch + Lomb.

Summary

Pulse Biosciences beats Bausch + Lomb on 8 of the 14 factors compared between the two stocks.

About Bausch + Lomb

Bausch + Lomb Corporation is an eye-health company that develops, manufactures and markets products for consumers, eye-care professionals and surgical teams. Its business spans vision care, pharmaceuticals and surgical devices. Its products include contact lenses and lens-care solutions, as well as eye-health medicines and nutritional supplements. The company also supplies equipment, technologies and related products used in eye surgery and other ophthalmic procedures. Founded in Rochester, New York, in 1853 by John Jacob Bausch and Henry Lomb, the company serves customers in more than 100 countries.

About Pulse Biosciences

Pulse Biosciences, Inc. develops medical devices using its proprietary nanosecond pulsed field ablation (nsPFA) technology. The technology delivers very short electrical pulses intended to disrupt targeted cells without relying on heat, with the goal of limiting effects on surrounding tissue. The company is developing nsPFA applications for cardiac electrophysiology and surgical oncology, including devices for tissue ablation. Its earlier CellFX System brought the technology to dermatology for treating certain benign skin lesions, marking an initial commercial application of the platform.